What changed
Novo Nordisk reported positive phase 2 headline results in 448 people with type 2 diabetes. The randomized dose-finding study compared oral and subcutaneous amycretin with placebo over up to 36 weeks.
What the evidence does not settle
Sponsor announcement, not an independent full-paper extraction. Population, dose and estimand matter; investigational results do not establish approval.
Evidence record
Event date: 2025-11-25. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.